PMID- 7687782 OWN - NLM STAT- MEDLINE DCOM- 19930824 LR - 20190913 IS - 0270-4137 (Print) IS - 0270-4137 (Linking) VI - 23 IP - 1 DP - 1993 TI - An immunocytochemical analysis of TGF alpha expression in benign and malignant prostatic tumors. PG - 9-23 AB - Transforming growth factor alpha (TGF alpha) expression was analyzed immunocytochemically on formalin-fixed wax-embedded sections obtained from 24 benign prostatic hyperplasia (BPH) specimens and 76 prostatic carcinoma tissues, 3 human prostatic tumor xenografts, normal kidney, and salivary gland. Low amounts of TGF alpha immunopositivity were encountered in the epithelium of BPH glandular tissues, whereas in the prostatic adenocarcinoma samples, a greater heterogeneity and intensity of TGF alpha immunostaining was observed. The most intense staining was exhibited by the least differentiated tumors, although a few of these were weakly stained. Statistical analysis of the relationship of histopathological grade of tumor with TGF alpha expression in the carcinomas showed a significant correlation of these parameters, 0.01 > P > 0.001. The expression of the proliferation markers Ki-67 and PCNA was also analyzed in the carcinoma specimens, and the relationship of these to TGF alpha expression indicated that there was no significant correlation in this series of tumors between increased growth activity and TGF alpha expression (p approximately 0.25 with both markers). The prostatic carcinoma xenografts TEN12 and TEN15 contained low levels of immunoreactive TGF alpha, which was uniformly distributed, whilst heterogeneous immunostaining was observed in the uroepithelial xenograft TEN16. In the normal human kidney, TGF alpha was concentrated in the epithelium of the distal convoluted tubules (DCT) and the collecting tubules (CT), and lower amounts were identified in the proximal convoluted tubules (PCT). As in the prostatic carcinomas, the immunostaining was eliminated by prior absorption of the antibody with pure TGF alpha and not with human or mouse EGF. No crossreactivity of the TGF alpha antibody with salivary EGF was demonstrated. This study concludes that, in prostate carcinoma, the least differentiated tumors more often expressed greater amounts immunoreactive TGF alpha; however, no relationship between TGF alpha expression and cellular proliferation markers was found. FAU - Harper, M E AU - Harper ME AD - Tenovus Institute for Cancer Research, University of Wales College of Medicine, Health Park, Cardiff, UK. FAU - Goddard, L AU - Goddard L FAU - Glynne-Jones, E AU - Glynne-Jones E FAU - Wilson, D W AU - Wilson DW FAU - Price-Thomas, M AU - Price-Thomas M FAU - Peeling, W B AU - Peeling WB FAU - Griffiths, K AU - Griffiths K LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Prostate JT - The Prostate JID - 8101368 RN - 0 (Antigens, Neoplasm) RN - 0 (Ki-67 Antigen) RN - 0 (Neoplasm Proteins) RN - 0 (Nuclear Proteins) RN - 0 (Proliferating Cell Nuclear Antigen) RN - 0 (Transforming Growth Factor alpha) SB - IM MH - Adenocarcinoma/chemistry/*metabolism/pathology MH - Adenocarcinoma, Papillary/chemistry/metabolism MH - Animals MH - Antigens, Neoplasm/analysis/biosynthesis MH - Carcinoma, Squamous Cell/chemistry/metabolism MH - Humans MH - Immunohistochemistry MH - Ki-67 Antigen MH - Kidney/chemistry/metabolism MH - Male MH - Mice MH - Mice, Nude MH - Neoplasm Proteins/analysis/biosynthesis MH - Neoplasm Transplantation MH - Nuclear Proteins/analysis/biosynthesis MH - Proliferating Cell Nuclear Antigen MH - Prostatic Hyperplasia/metabolism MH - Prostatic Neoplasms/chemistry/*metabolism/pathology MH - Submandibular Gland/chemistry/metabolism MH - Transforming Growth Factor alpha/analysis/*biosynthesis EDAT- 1993/01/01 00:00 MHDA- 1993/01/01 00:01 CRDT- 1993/01/01 00:00 PHST- 1993/01/01 00:00 [pubmed] PHST- 1993/01/01 00:01 [medline] PHST- 1993/01/01 00:00 [entrez] AID - 10.1002/pros.2990230103 [doi] PST - ppublish SO - Prostate. 1993;23(1):9-23. doi: 10.1002/pros.2990230103.